Article, News
Prescient to announce Phase 1b cancer trial results at world’s largest haematology conference
Prescient Therapeutics (ASX:PTX) has announced that its abstract for the results of a Phase 1b study in T-cell lymphomas has been accepted for poster presentation…
Article, News
Prescient Therapeutics to present clinical data at prestigious US conference
Results of a Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) Phase 1b study in T cell lymphomas have been accepted for poster presentation at the prestigious American Society of Hematology…
Article, News
Why are clinical advances by this small-cap ASX biotech in FY23 so significant?
Prescient Therapeutics Limited (ASX: PTX) has been witnessing significant achievements and progress towards its goal of developing targeted cancer treatments. In the latest financial year…
Article, News
Prescient Therapeutics prepares for ‘pivotal’ year of PTX-100 development to treat T-cell lymphomas
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023 which it says has set the stage for a pivotal…
Article, News
‘Above and beyond approved therapies’: How Prescient Therapeutics is at the forefront of cancer fighting
Prescient Therapeutics is on a mission to improve outcomes for cancer patients, and it is making progress with a diverse portfolio of later and early-stage…
News
Prescient data readout approaching with phase 2 trial around the corner
Prescient Therapeutics (ASX: PTX) had a solid FY23 that has set the stage for a pivotal year to come. Front and centre of the company’s…
Article, News
Prescient Therapeutics (ASX:PTX) – TechKnow Invest Roadshow, August 2023
Steven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted…
Article, News
Strong quarter for Prescient bolsters future of further trials
Clinical stage oncology company Prescient Therapeutics Ltd (ASX: PTX) has finished off another strong quarter with a healthy $21.8 million cash balance that will serve…
Article, News
TechKnow Invest Roadshow
Hear Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke present at the TechKnow Invest Roadshow – Gold Coast.